PMID- 26977012
OWN - NLM
STAT- MEDLINE
DCOM- 20161107
LR  - 20181202
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 36
IP  - 3
DP  - 2016 Mar
TI  - A Novel NHERF1 Mutation in Human Breast Cancer Inactivates Inhibition by NHERF1 
      Protein in EGFR Signaling.
PG  - 1165-73
AB  - BACKGROUND: Na(+)/H(+) exchanger regulatory factor 1 (NHERF1) has been reported 
      to interact with many cancer-related proteins. We recently identified a novel 
      NHERF1 mutation (E43G) in breast tumours. MATERIALS AND METHODS: The candidates 
      of NHERF1 mutation were identified in breast cancer tissues by polymerase chain 
      reaction and DNA sequencing. Wild-type NHERF1 and E43G mutation were expressed in 
      NHERF1-knockdown cells (MCF7DeltaNHERF1) and low-NHERF1-expressing cells (SKMES-1). 
      The effects of mutated NHERF1 on cell functions were examined using in vitro 
      methods. Glutathione S-transferase pull-down assays and western blotting were 
      performed to study the effects of NHERF1 mutation on its interaction with 
      cancer-related proteins. RESULTS: Compared to wild-type NHERF1, expression of the 
      mutated NHERF1 failed to suppress malignant traits in cancer cells, attenuated 
      interaction of NHERF1 protein with epidermal growth factor receptor (EGFR), and 
      inactivated its inhibition of EGF-induced Akt and extracellular regulated protein 
      kinases (ERK) activation. CONCLUSION: The results show the causal role of NHERF1 
      in the regulation of the EGFR pathway and the progression of breast cancer.
CI  - Copyright(c) 2016 International Institute of Anticancer Research (Dr. John G. 
      Delinassios), All rights reserved.
FAU - DU, Guifang
AU  - DU G
AD  - Department of Biochemistry and Molecular Biology, Capital Medical University, 
      Beijing, P.R. China Beijing Key Laboratory of Cancer & Metastasis Research, 
      Capital Medical University, Beijing, P.R. China.
FAU - Hao, Chengcheng
AU  - Hao C
AD  - Department of Biochemistry and Molecular Biology, Capital Medical University, 
      Beijing, P.R. China Beijing Key Laboratory of Cancer & Metastasis Research, 
      Capital Medical University, Beijing, P.R. China.
FAU - Gu, Yanan
AU  - Gu Y
AD  - Department of Biochemistry and Molecular Biology, Capital Medical University, 
      Beijing, P.R. China Beijing Key Laboratory of Cancer & Metastasis Research, 
      Capital Medical University, Beijing, P.R. China.
FAU - Wang, Zhiyan
AU  - Wang Z
AD  - Department of Biochemistry and Molecular Biology, Capital Medical University, 
      Beijing, P.R. China Beijing Key Laboratory of Cancer & Metastasis Research, 
      Capital Medical University, Beijing, P.R. China.
FAU - Jiang, Wen G
AU  - Jiang WG
AD  - Department of Biochemistry and Molecular Biology, Capital Medical University, 
      Beijing, P.R. China Beijing Key Laboratory of Cancer & Metastasis Research, 
      Capital Medical University, Beijing, P.R. China Cardiff China Medical Research 
      Collaborative, Cardiff University School of Medicine, Heath Park, Cardiff, U.K.
FAU - He, Junqi
AU  - He J
AD  - Department of Biochemistry and Molecular Biology, Capital Medical University, 
      Beijing, P.R. China Beijing Key Laboratory of Cancer & Metastasis Research, 
      Capital Medical University, Beijing, P.R. China chengs@ccmu.edu.cn 
      jq_he@ccmu.edu.cn.
FAU - Cheng, Shan
AU  - Cheng S
AD  - Department of Biochemistry and Molecular Biology, Capital Medical University, 
      Beijing, P.R. China Beijing Key Laboratory of Cancer & Metastasis Research, 
      Capital Medical University, Beijing, P.R. China chengs@ccmu.edu.cn 
      jq_he@ccmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Phosphoproteins)
RN  - 0 (Sodium-Hydrogen Exchangers)
RN  - 0 (sodium-hydrogen exchanger regulatory factor)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
SB  - IM
MH  - Breast Neoplasms/genetics/*metabolism
MH  - Cell Adhesion
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Enzyme Activation
MH  - Epidermal Growth Factor/pharmacology
MH  - ErbB Receptors/agonists/*metabolism
MH  - Extracellular Signal-Regulated MAP Kinases/metabolism
MH  - Humans
MH  - MCF-7 Cells
MH  - Male
MH  - *Mutation
MH  - Neoplasm Invasiveness
MH  - Phenotype
MH  - Phosphoproteins/genetics/*metabolism
MH  - Protein Binding
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - *Signal Transduction/drug effects
MH  - Sodium-Hydrogen Exchangers/genetics/*metabolism
MH  - Transfection
OTO - NOTNLM
OT  - EGFR
OT  - NHERF1 mutation
OT  - breast cancer
EDAT- 2016/03/16 06:00
MHDA- 2016/11/08 06:00
CRDT- 2016/03/16 06:00
PHST- 2016/03/16 06:00 [entrez]
PHST- 2016/03/16 06:00 [pubmed]
PHST- 2016/11/08 06:00 [medline]
AID - 36/3/1165 [pii]
PST - ppublish
SO  - Anticancer Res. 2016 Mar;36(3):1165-73.